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General procedures: All reactions were carried out in flame-dried glassware under Argon. All the 
solvents were purified by distillation over the drying agents indicated and were transferred under 
Argon. CH2Cl2 (CaH2), hexane, toluene (Na/K). Flash chromatography: Merck silica gel 60 (230-400 
mesh). IR: Nicolet FT-7199 spectrometer, wavenumbers in cm-1. MS (EI): Finnigan MAT 8200 (70 eV), 
ESI-MS: Finnigan MAT 95, accurate mass determinations: Bruker APEX III FT-MS (7 T magnet). 
NMR: Spectra were recorded on a Bruker DPX 300 or AV 400 spectrometer in the solvents indicated; 
1H and 13C chemical shifts (δ) are given in ppm relative to TMS, coupling constants (J) in Hz. The 
solvent signals were used as references and the chemical shifts converted to the TMS scale. All 
commercially available compounds (Acros, Fluka, Lancaster, Alfa Aesar, Aldrich) were used as 
received unless stated otherwise. Compounds 71, 352 and 373 were prepared accordingly to the 
procedure described in the literature.
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General procedure for the Alkylation of 2-Chloropyridines. A solution of the 
corresponding 2-chloropyridine (1 equiv.) in DCM (0.05 M) was added to solid Me3OBF4 or 
Et3OBF4 (1 equiv.) and the suspension stirred overnight. Then, the solvent was filtered off 
and the remaining white solid washed twice with dichloromethane and dried in vacuum. 
 
Compound 6: Prepared from 2-chloropyridine (2.0 g, 17.6 mmol) and Me3OBF4 
(2.6 g, 17.6 mmol) following the general procedure. After washing with DCM (2 x 
20 ml), 6 was obtained as a white solid (3.47 g, 91%).  
1H NMR (300 MHz, CD3CN) δ = 8.75 (d, J = 6.2 Hz, 1H), 8.47 (td, J = 8.2, 1.5 Hz, 
1H), 8.12 (d, J = 8.3 Hz, 1H), 7.94 (t, 3J = 6.8 Hz, 1H), 4.30 (s, 3H); 13C NMR (75 MHz, 
CD3CN) δ = 148.98, 148.96, 148.38, 131.00, 127.40, 48.62; IR (neat) ṽ = 712, 735, 778,  
805, 1024, 1123, 1177, 1274, 1286, 1314, 1446, 1499, 1574, 1623, 3059, 3094, 3115, 3138 
cm-1 HRMS calcd. for C12H14BCl2F4N2: 343.056684; found: 343.056646. 
 
 
Compound 8: Prepared from 2-chloro-5-fluoropyridine (1.0 g, 7.6 mmol) and 
Me3OBF4 (1.12 g, 7.6 mmol) following the general procedure. After washing 
with DCM (2 x 20 ml), 8 was obtained as a white solid (1.75 g, 99%).  
1H NMR (300 MHz, CD3CN) δ = 8.88 (t, J = 3.1 Hz, 1H), 8.36 (ddd, J = 9.4, 
6.7, 2.9 Hz, 1H), 8.16 (dd, J = 9.3, 4.9 Hz, 1H), 4.31 (s, 3H); 13C NMR (75 MHz, CD3CN) δ = 
159.92 (d, JC-F = 255.1 Hz), 145.62, 138.70 (d, JC-F = 40.0 Hz), 136.23 (d, JC-F = 19.8 Hz), 
132.21 (d, JC-F = 7.9 Hz), 49.46; 19F NMR (282 MHz, CD3CN) δ = -120.22, -151.77, -151.82; 
IR (neat) ṽ = 655, 698, 743, 767, 854, 901, 1022, 1126, 1165, 1282, 1392, 1439, 1509, 1593, 
1641, 3084, 3104 cm-1; HRMS calcd. for C12H12N2BCl2F6: 379.036928; found: 379.037035. 
 
 
Compound 9: Prepared from 2-chloro-5-(trifluoromethyl)pyridine (400 mg, 
2.2 mmol) and Me3OBF4 (325 mg, 2.2 mmol) following the general 
procedure.  After washing with DCM (2 x 2 ml), 9 was obtained as a white 
solid (620 mg, 99%).  
1H NMR (300 MHz, CD3CN) δ = 9.23 (s, 1H), 8.75 (dd, J = 8.7, 2.0 Hz, 1H), 8.34 (d, J = 8.7 
Hz, 1H), 4.39 (s, 3H); 13C NMR (75 MHz, CD3CN) δ = 153.30, 147.41 (m), 144.96 (q, JC-F = 
3.0 Hz), 132.13, 129.37 (q, JC-F = 37.0 Hz), 122.32 (q, JC-F = 272.7 Hz), 49.45; 19F NMR (282 
MHz, CD3CN) δ = -63.45, -151.99, -152.04; IR (neat) ṽ = 663, 690, 722, 804, 861, 888, 916, 
944, 998, 1025, 1125, 1192, 1268, 1331, 1435, 1479, 1590, 1639, 2296, 2342, 2383, 3055 




Compound 11: Prepared from 2-chloro-5-methoxypyridine (965 mg, 
6.72 mmol) and Me3OBF4 (994 mg, 6.72 mmol) in DCM (20 ml) following 
the general procedure.  After washing with DCM (2 x 20 ml), 11 was 
obtained as a white solid (1.47 g, 89%). 
1H NMR (300 MHz, CD3CN) δ = 8.47 (d, J = 2.7 Hz, 1H), 8.10 – 7.93 (m, 2H), 4.27 (s, 3H), 
4.00 (s, 3H); 13C NMR (75 MHz, CD3CN) δ = 158.33, 140.00, 136.02, 134.07, 130.94, 58.76, 
48.98; 19F NMR (282 MHz, CD3CN) δ = -151.67, -151.72; IR (neat) ṽ = 697, 739, 847, 875, 
936, 1013, 1037, 1099, 1159, 1177, 1197, 1271, 1308, 1391, 1425, 1445, 1469, 1513, 1590, 
1622, 3101, 3156 cm-1; HRMS calcd. for C14H18N2BCl2F4O2: 403.077864; found: 403.078070. 
 
 
Compound 10: Prepared from 2-chloro-5-(trifluoromethyl)pyridine (1 g, 5.5 
mmol) and Et3OBF4 (1.05 g, 5.5 mmol) in DCM (20 ml) following the general 
procedure and purified by filtration and washing with DCM (2 x 10 ml) to 
afford 10 as a white solid (1.6 g, 5.4 mmol, 99%).  
1H NMR (300 MHz, CD3CN) δ = 9.24 (d, J = 0.7 Hz, 1H), 8.74 (dd, J = 8.7, 2.1 Hz, 1H), 8.34 
(d, J = 8.7 Hz, 1H), 4.82 (q, J = 7.3 Hz, 2H), 1.62 (t, J = 7.3 Hz, 3H) ; 13C NMR (75 MHz, 
CD3CN) = 152.27, 146.25, 144.89 (q, JC-F = 3.0 Hz), 132.79, 129.92 (q, JC-F = 36.9 Hz), 
122.21 (q, JC-F = 273.7 Hz); 19F NMR (282 MHz, CD3CN) δ = -63.46, -151.88, -151.94; IR 
(neat) ṽ =727, 740, 767, 809, 858, 939, 1023, 1056, 1095, 1110, 1146, 1183, 1193, 1233, 
1299, 1328, 1395, 1413, 1453, 1473, 1509, 1586, 1639, 3089 cm-1; HRMS calcd. for 
C8H8NClF3: 210.029185; found: 210.028857. 
 
 
General procedure for the Preparation of Pyridiniophosphines. To a solution of the 
corresponding 1-alkyl/aryl-2-chloropyridinium tetrafluoroborate (1 equiv.) in THF (2 ml) was 
added the desired secondary phosphine (2.5-3.0 equiv.) and the resulting suspension heated 
for 1 to 7 days. After cooling to rt, the solvents were evaporated and the crude reaction 
mixture washed with n-Pentan (2 x 2 ml), solved in DCM and washed with sat. NaBF4 
aqueous solution. The organic phase was dried over NaSO4 and the solvent evaporated. If 
necessary, the resulting solid could be further purified by an additional wash with THF (1-2 
ml). 
 
Compound 12: Prepared by heating a THF suspension of 6 (400 mg, 1.8 
mmol) and diphenylphosphine (1.1 ml, 5.6 mmol) at 65°C for 3 days. White 
solid (477 mg, 70%).  
  
1H NMR (300 MHz, CDCl3) δ = 9.04 (d, J = 5.7 Hz, 1H), 8.25 (td, J = 7.9, 0.9 Hz, 1H), 8.03 – 
7.95 (m, 1H), 7.57 – 7.43 (m, 6H), 7.39 – 7.27 (m, 5H), 4.30 (d, J = 1.1 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ = 161.02 (d, JC-P = 33.4 Hz), 149.54, 144.04, 134.70 (d, JC-P = 21.7 Hz), 
132.63, 131.60, 130.20 (d, JC-P = 8.4 Hz), 129.03 (d, J = 6.7 Hz), 127.96, 47.64 (d, JC-P = 
21.0 Hz); 31P NMR (121 MHz, CDCl3) δ = -8.61; IR (neat) ṽ = 696, 724, 748, 798, 954, 1000, 
1038, 1051, 1161, 1181, 1265, 1310, 1436, 1492, 1571, 1610, 3055, 3103, 3134 cm-1; 
HRMS calcd. for C18H17NP: 278.109315; found: 278.109239. 
 
 
Compound 13: Prepared by heating a THF suspension of 6 (500 mg, 2.3 
mmol) and dicyclohexylphosphine (0.75 ml, 5.8 mmol) at 65°C for 3 days. 
White solid (699 mg, 80%).  
 1H NMR (400 MHz, CDCl3) δ = 9.11 (d, J = 5.2 Hz, 1H), 8.48 (t, J = 7.8 Hz, 1H), 8.05 (dd, J = 
14.3, 7.5 Hz, 2H), 4.59 (s, 3H), 2.11 (t, J = 11.8 Hz, 2H), 1.91 (d, J = 12.0 Hz, 2H), 1.81 (d, J 
= 12.8 Hz, 2H), 1.69 (t, J = 11.9 Hz, 4H), 1.51 (d, J = 12.5 Hz, 2H), 1.41 – 1.01 (m, 10H); 13C 
NMR (101 MHz, CDCl3) δ = 160.33 (d, JC-P = 42.5 Hz), 149.73, 143.58, 133.44 (d, JC-P = 3.2 
Hz), 128.24, 48.82 (d, JC-P = 26.1 Hz), 34.36 (d, JC-P = 15.1 Hz), 29.95 (d, JC-P = 15.9 Hz), 
29.44 (d, JC-P =8.6 Hz), 26.78 (d, JC-P = 12.5 Hz), 26.65 (d, JC-P = 8.8 Hz), 25.91; 31P NMR 
(162 MHz, CDCl3) δ = -3.52; IR (neat) ṽ = 728, 779, 851, 915, 1053, 1179, 1262, 1448, 1497, 
1571, 1610, 2851, 2925 cm-1; HRMS calcd. for C18H29NP: 290.203217; found: 290.203415. 
 
 
Compound 14: Prepared by heating a THF suspension of 7 (650 mg, 2.3 
mmol) and diphenylphosphine (1.2 ml, 6.9 mmol) at 130°C for 12 h in a 
µwave oven. White solid (715 mg, 71%).  
1H NMR (300 MHz, CDCl3) δ = 8.76 (d, J = 5.1 Hz, 1H), 8.46 (td, J = 8.0 Hz, 1.3, 1H), 8.06 (t, 
J = 6.9 Hz, 1H), 7.66 – 7.50 (m, 4H), 7.50 – 7.37 (m, 6H), 7.32 – 7.21 (m, 6H); 13C NMR (75 
MHz, CD3CN) δ = 149.53, 146.74, 135.83 (d, JC-P = 22.5 Hz), 134.40, 132.53, 132.11, 131.40 
(d, JC-P = 8.2 Hz), 130.58 (d, JC-P = 7.6 Hz), 128.25, 127.40 (d, JC-P = 3.8 Hz); 19F NMR (282 
MHz, CDCl3) δ = -151.82, -151.87; 31P NMR (121 MHz, CDCN) δ = -7.74; IR (neat) ṽ = 692, 
699, 734, 748,757, 786, 841, 863, 901, 931, 979, 997, 1011, 1035, 1047, 1079, 1163, 1178, 
1254, 1288, 1315, 1438, 1455, 1475, 1492, 1563, 1589, 1607, 3070, 3117 cm-1; HRMS 




Compound 15: Prepared by heating a THF suspension of 8 (500 mg, 2.14 
mmol) and diphenylphosphine (0.92 ml, 5.35 mmol) at 65°C for 3 days. 
White solid (351 mg, 43%). 
1H NMR (300 MHz, CD3CN) δ = 8.94 – 8.82 (m, 1H), 8.18 – 8.07 (m, 1H), 7.58 (m, 6H), 7.42 
(m, 5H), 4.23 (d, J = 1.4 Hz, 3H); 13C NMR (75 MHz, CDCN) δ = 160.91 (d, JC-F = 255.7 Hz), 
139.81 (d, JC-P = 38.2 Hz), 135.66 (d, JC-P = 0.9 Hz), 135.62 (d, JC-P = 21.9 Hz), 132.84 (d, 
JC-P = 17.4 Hz), 132.43 (d, JC-P = 0.6 Hz), 130.92 (d, JC-P = 8.3 Hz), 130.28 (d, JC-P = 6.7 Hz), 
49.12 (d, JC-P = 21.5 Hz); 31P NMR (121 MHz, CDCl3) δ = -9.34; IR (neat) ṽ = 699, 715, 738, 
753, 760, 858, 895, 931, 958, 998, 1024, 1143, 1165, 1181, 1273, 1314, 1384, 1436, 1479, 
1500, 1583, 1623 cm-1; HRMS calcd. for C18H16NFP: 296.099965; found: 296.099889. 
 
 
Compound 16: Prepared by heating a THF suspension of 9 (500 mg, 
1.8 mmol) and diphenylphosphine (0.62 ml, 4.4 mmol) at 65°C for 1 day. 
White solid (451 mg, 60%).  
1H NMR (300 MHz, CD3CN) δ = 9.18 (s, 1H), 8.51 (dd, J = 8.4, 1.3 Hz, 
1H), 7.72 – 7.50 (m, 7H), 7.50 – 7.38 (m, 4H), 4.25 (d, J = 1.0 Hz, 3H); 13C NMR (75 MHz, 
CD3CN) δ = 167.44 (d, JC-P = 35.6 Hz), 147.74, 141.70 (q, JC-F = 3.0 Hz), 135.92 (d, JC-P = 
22.0 Hz), 134.82 (d, JC-P = 1.2 Hz), 132.72, 131.05 (d, JC-P = 8.6 Hz), 129.85 (q, JC-F = 36.1), 
129.43 (d, JC-P = 6.0 Hz), 122.51 (q, JC-F = 272.6 Hz), 49.24 (d, JC-P = 20.7); 19F NMR (282 
MHz, CD3CN) δ = -63.67, -151.79, -151.84; 31P NMR (121 MHz, CD3CN) δ = -6.00; IR (neat) 
ṽ = 693, 702, 727, 743, 752, 862, 892, 913, 996, 1048, 1090, 1115, 1148, 1174, 1267, 1342, 




Compound 17: Prepared by heating a THF suspension of 8 (500 mg, 2.14 
mmol) and dicyclohexylphosphine (1.08 ml, 5.35 mmol) at 65°C during 12 
hours. White solid (648 mg, 77%).  
1H NMR (300 MHz, CDCl3) δ = 9.06 (d, J = 2.3 Hz, 1H), 8.34 – 8.21 (m, 1H), 8.21 – 8.08 (m, 
1H), 4.64 (s, 3H), 2.12 (t, J = 11.5 Hz, 2H), 1.98 – 1.61 (m, 8H), 1.52 (d, J = 11.7 Hz, 2H), 
1.44 – 1.02 (m, 10H); 13C NMR (75 MHz, CD3CN) δ = 160.88 (d, JC-F = 255.9 Hz), 158.18 
(dd, JC-P = 43.7, JC-F = 4.2 Hz), 140.06 (d, JC-P = 36.1 Hz), 136.29 (dd, JC-P = 7.4 Hz, JC-F = 3.4 
Hz), 131.93 (d, JC-P = 17.2 Hz), 50.13 (d, JC-P = 26.4 Hz), 34.72 (d, JC-P = 14.3 Hz), 30.48 (d, 
JC-P = 16.2 Hz), 30.01 (d, JC-P = 8.7 Hz), 27.42 (d, JC-P = 10.9 Hz), 27.28 (d, JC-P = 10.9 Hz), 
26.61; 19F NMR (282 MHz, CDCl3) δ = -118.61, -151.62, -151.67; 31P NMR (121 MHz, 






1057, 1112, 1170, 1182, 1202, 1269, 1279, 1433, 1450, 1504, 1582, 1626, 2852, 2925, 3077 
cm-1; HRMS calcd. for C18H17NP: 308.193442; found: 308.193793. 
 
 
Compound 18: Prepared by heating a THF suspension off 11 (500 mg, 
2.05 mmol) and dicyclohexylphosphin (1.25 ml, 6.16 mmol) at 65°C 
during 12 hours. White solid (744 mg, 89%). 
1H NMR (300 MHz, CDCl3) δ = 8.48 (d, J = 2.1 Hz, 1H), 8.04 (d, J = 9.0 Hz, 1H), 7.94 (dd, 
J = 9.0, 2.6 Hz, 1H), 4.43 (s, 3H), 4.01 (s, 3H), 2.21 – 2.08 (m, 2H), 1.85 – 0.96 (m, 20H); 13C 
NMR (75 MHz, CD3CN) δ = 159.15, 138.13, 135.35, 135.31, 58.35, 49.85 (d, JC-P = 27.5 Hz), 
34.82 (d, JC-P = 13.5 Hz), 30.76 (d, JC-P = 16.9 Hz), 29.97 (d, JC-P = 8.1 Hz), 27.48 (d, J = 13.2 
Hz), 27.34 (d, JC-P = 8.8 Hz), 26.73 (d, JC-P = 1.1 Hz); 19F NMR (282 MHz, CDCl3) δ = 
-151.83, -151.88 ; 31P NMR (121 MHz, CDCN) δ = -7.27; IR (neat) ṽ = 704, 741, 816, 842, 
884, 916, 1000, 1015, 1035, 1046, 1163, 1187, 1196, 1286, 1317, 1434, 1447, 1507, 1574, 
1615, 2845, 2920 cm-1; HRMS calcd. for C19H31NOP: 320.213778; found: 320.213335. 
 
 
Compound 19: To a suspension of KH (8.75 mg, 0.22 mmol) in 
THF (2 ml) was added bis(3,5-bis(trifluoromethyl)phenyl) 
phosphine (100 mg, 0.22 mmol) at -78 °C and the resulting deep 
red suspension stirred for 1 hour. Then, the suspension was 
transferred at the same temperature to a precooled suspension 
(-78 °C) of 10 (64.9 mg, 0.22 mmol) in THF (2 ml) and the mixture 
allowed to warm up to rt and stirred for 3 days. After evaporation of the solvent and washing 
with DCM (2x 2ml), compound 19 was obtained as an off white solid (48 mg, 30%).  
1H NMR (300 MHz, CDCl3) δ = 9.32 (s, 1H), 8.62 (d, J = 7.7 Hz, 1H), 8.25 (s, 2H), 8.02 (d, J 
= 7.2 Hz, 4H), 7.92 (d, J = 7.9 Hz, 1H), 4.88 (m, 2H), 1.56 (t, J = 7.3 Hz, 3H); 13C NMR (75 
MHz, CD3CN) δ = 161.99 (d, JC-P = 33.4 Hz), 147.95 – 146.40 (m), 143.99 – 142.39 (m), 
137.44, 136.89 – 136.01 (m), 133.59 (qd, JC-F =33.9 Hz, JC-P = 7.7 Hz), 133.19 (d, JC-P = 13.5 
Hz), 132.18 (d, JC-P = 36.9 Hz), 124.10 (q, JC-F = 272.4 Hz), 121.46 (q, JC-F = 273.0 Hz), 58.60 
(d, JC-P = 23.4 Hz), 16.29 (d, JC-P = 3.5 Hz); 19F NMR (282 MHz, CDCl3) δ = -63.52, -63,68, 
-151.80, -151.85; 31P NMR (121 MHz, CDCN) δ = -10.52; IR (neat) ṽ = 682, 700, 741, 767, 
846, 862, 900, 913, 1051, 1095, 1120, 1279, 1331, 1356, 1405, 1459, 1502, 1588, 1634, 




General procedure for the preparation of pyridiniophosphine rhodium complexes: 
[Rh(CO)2Cl]2 (0.25 equiv.) was added to a solution of the corresponding pyridiniophosphine 
ligand (1 equiv.) in DCM (2 ml). The resulting suspension was stirred for 1 hour at rt and after 
evaporation of the solvent, the solid was washed with n-pentan (2 x 2 ml) and dried in 
vacuum. These compounds can be crystalized from acetonitrile/ether mixtures.  
 
Compound 20: Prepared from 12 (100 mg, 0.274 mmol) and 
[Rh(CO)Cl2]2 (26.6 mg, 0.063 mmol) following the general procedure. 
Yellow solid (121 mg, 99%).  
1H NMR (300 MHz, CDCN) δ = 8.84 (d, J = 5.9 Hz, 2H), 8.38 (t, J = 7.7 
Hz, 2H), 8.11 – 8.02 (m, 2H), 7.84 (s, 8H), 7.79 – 7.72 (m, 4H), 7.72 – 
7.58 (m, 10H), 4.50 (s, 6H); 13C NMR (75 MHz, CDCN) δ = 186.07 (dt, JC-Rh = 31.9 Hz, JC-P = 
15.6 Hz), 153.59 (t, JC-P = 18.1 Hz), 151.14, 145.60, 136.20, 134.99, 134.20, 131.14, 130.07, 
126.58 (t, JC-P = 24.3 Hz), 50.82; 31P NMR (121 MHz, CDCN) δ = 37.82 (d, JP-Rh = 130.7 Hz); 
IR (neat) ṽ = 692, 707, 752, 773, 799, 900, 931, 998, 1056, 1165, 1182, 1274, 1314, 1411, 
1438, 1481, 1499, 1576, 1610, 1996, 3093, 3138 cm-1; HRMS calcd. for 
C37H34BClF4N2OP2Rh: 809.092884; found: 809.093025. 
 
 
Compound 21: Prepared from 15 (75 mg, 0.2 mmol) and [Rh(CO)2Cl]2 
(19.3 mg, 0.05 mmol) following the general procedure. Yellow solid 
(121 mg, 69%).  
1H NMR (300 MHz, CDCN) δ = 8.98 (s, 2H), 8.27 – 8.16 (m, 2H), 7.84 
(s, 8H), 7.76 (t, J = 7.4 Hz, 4H), 7.68 (t, J = 7.6 Hz, 10H), 4.54 (s, 6H); 
13C NMR (75 MHz, CDCN) δ = 161.59 (d, JC-F = 259.3 Hz), 150.65, 
141.69 (d, JC-F = 38.2 Hz), 136.72 (d, JC-P = 8.5 Hz), 136.17, 134.35, 132.75 (d, JC-F = 17.3 
Hz), 131.22, 126.48, 51.51 (d, JC-P = 1.6 Hz); 31P NMR (121 MHz, CDCN) δ = 39.02 (d, JRh-P 
= 130.7 Hz); IR (neat) ṽ = 694, 738, 754, 850, 962, 998, 1054, 1169, 1282, 1437, 1482, 




Compound 22: Prepared from 16 (100 mg, 0.231 mmol) and 
[Rh(CO) 2Cl]2 (22.5 mg, 0.058 mmol) following the general 
procedure. Yellow solid (68 mg, 57%).  
1H NMR (300 MHz, CDCN) δ = 9.28 (s, 2H), 8.65 (d, J = 8.2 Hz, 
2H), 7.95 – 7.63 (m, 22H), 4.56 (s, 6H); 13C NMR (75 MHz, CDCN) 
  
δ = 167.45 (d, JC-P = 36.8 Hz), 147.80, 141.73, 136.46 (d, JC-P = 22.1 Hz), 134.84, 132.76, 
131.08 (d, JC-P = 8.5 Hz), 129.81 (d, JC-P = 36.7 Hz), 129.44 (d, JC-P = 5.4 Hz), 122.54 (q, JC-F 
= 272.8 Hz), 47.26 (d, JC-P = 20.6 Hz); 31P NMR (121 MHz, CDCN) δ = 40.44 (d, JRh-P = 131.0 
Hz); IR (neat) ṽ = 691, 705, 752, 858, 890, 932, 998, 1052, 1090, 1118, 1159, 1177, 1243, 
1275, 1334, 1392, 1438, 1482, 1509, 1586, 1634, 1741, 2004, 3092 cm-1; HRMS calcd. for 
C39H32BClF10N2OP2Rh: 945.067689; found: 945.067581. 
 
 
Compound 23: Prepared from 14 (100 mg, 0.253 mmol) and [Rh(CO) 
2Cl]2 (24.6mg, 0.063 mmol) following the general procedure. Yellow 
solid (94 mg, 78%).  
1H NMR (300 MHz, CDCl3) δ =8.62 (d, J = 5.6 Hz, 2H), 8.49 (t, J = 7.9 
Hz, 2H), 8.17 – 8.07 (m, 4H), 7.78 (dd, J = 12.7, 6.3 Hz, 8H), 7.54 (ddd, 
J =22.9, 14.9, 7.8 Hz, 16H), 7.33 (t, J = 7.5 Hz, 2H), 6.91 (t, J = 8.0 Hz, 4H); 13C NMR (101 
MHz, CDCN) δ = 154.96, 151.72, 146.24, 142.28, 136.52 (t, JC-P = 7.2 Hz), 136.12 – 135.26 
(m), 133.73, 132.75, 130.74 (t, JC-P = 5.5 Hz), 130.48, 129.97, 128.15, 127.91, 127.71; 31P 
NMR (121 MHz, CDCl3) δ = 42.09 (d, JRh-P = 134.4 Hz); IR (neat) ṽ = 692, 749, 925, 998, 
1034, 1048, 1182, 1254, 1286, 1318, 1437, 1457, 1479, 1587, 1603, 1981, 2350, 3060 cm-1; 
HRMS calcd. for C47H38BClF4N2OP2Rh: 933.124354; found: 933.123835. 
 
 
 Compound 24: Prepared from 18 (75 mg, 0.184 mmol) and 
[Rh(CO)2Cl]2 (17.9 mg, 0.046 mmol) following the general 
procedure. Yellow solid (67 mg, 74%).  
1H NMR (300 MHz, DMSO) δ = 9.11 (s, 2H), 8.38 (d, J = 9.1 Hz, 
2H), 8.20 (dd, J = 9.0, 2.3 Hz, 2H), 4.90 (s, 6H), 4.08 (s, 6H), 2.17 
(s, 4H), 2.02 – 0.94 (m, 40H); 13C NMR (101 MHz, DMSO) δ = 
185.13 (dt, JC-Rh = 33.4 Hz, JC-P = 16.4 Hz), 158.14, 140.35, 
138.33 (t, JC-P = 12.9 Hz), 134.89, 127.44, 57.59, 51.11 (t, JC-P = 4.2 Hz), 36.04, 33.28, 29.39, 
28.39, 27.61, 26.59, 25.77, 25.49; 31P NMR (121 MHz, DMSO) δ = 40.26 (d, JRh-P = 123.0 
Hz) ; IR (neat) ṽ = 706, 739, 765, 815, 854, 888, 918, 940, 1018, 1050, 1098, 1172, 1180, 
1207, 1269, 1317, 1415, 1450, 1475, 1515, 1614, 1974, 2850, 2928 cm-1; HRMS calcd. for 
C39H62BClF4N2O3P2Rh:  893.301860; found:  893.302947. 
 
 
General procedure for the preparation of the phosphine platinum complexes. Finely 
grounded K2PtCl4 (1 equiv ) was added to a solution of the pyridiniophosphine salt (1 equiv.) 
  
in MeCN (2 ml) and the resulting suspension stirred overnight at rt. After evaporation of the 
solvent, the solid was washed with n-Pentan (2 x 2 ml), crystallized from DMSO/DCM and 
dried in vacuum to yield the desired platinum complexes. 
 
 
Compound 28: Prepared from 12 (100 mg, 0.274 mmol) and K2PtCl4 
(114 mg, 0.274 mmol) following the general procedure. White solid (127 mg, 
80%).  
1H NMR (300 MHz, DMSO) δ = 9.18 (d, J = 5.7 Hz, 1H), 8.53 (t, J = 7.9 Hz, 1H), 8.20 (t, J = 
6.9 Hz, 1H), 8.02 (dd, J = 12.3 Hz, J = 7.2 Hz, 4H), 7.79 – 7.57 (m, 6H), 7.39 (t, J = 7.0 Hz, 
1H), 4.35 (s, 3H); 13C NMR (75 MHz, CD3CN) δ = 150.13, 144.54 (d, JC-P = 5.7 Hz), 135.32 
(d, JC-P = 11.6 Hz), 132.81 (d, JC-P = 7.5 Hz), 132.63 (d, JC-P = 2.5 Hz), 129.28 (d, JC-P = 11.6 
Hz), 128.78, 124.56, 123.71, 48.32 (d, JC-P = 7.3 Hz); 31P NMR (121 MHz, DMSO) δ = 8.49 
(JC-Pt = 1954 Hz); IR (neat) ṽ = 673, 822, 1003, 1023, 1051, 1659, 2126, 2253, 2342, 2383 
cm-1; HRMS for DMSO adduct calcd. for C20H23Cl2NOPPtS: 621.024487; found: 621.024734. 
 
 
Compound 29: Prepared from 16 (100 mg, 0.231 mmol) and K2PtCl4 
(96 mg, 0.231 mmol) following the general procedure. White solid 
(59 mg, 40%).  
1H NMR (300 MHz, DMSO) δ = 9.85 (s, 1H), 8.98 (d, J = 8.2 Hz, 1H), 
8.05 (dd, J = 12.4 Hz, J = 7.4 Hz, 4H), 7.81 – 7.60 (m, 6H), 7.55 (dd, J = 7.5 Hz, J = 7.1 Hz, 
1H), 4.42 (s, 3H); 13C NMR (75 MHz, CD3CN) δ = 155.07 (d, JC-P = 46.9 Hz), 148.54, 141.59, 
135.47 (d, JC-P = 11.7 Hz), 133.48 (d, JC-P = 7.7 Hz), 132.99, 129.46 (d, JC-P = 11.6 Hz), 
128.77 (d, JC-P = 36.1 Hz), 123.54 (d, JC-P = 64.0 Hz), 121.24 (q, JC-P = 273.6 Hz), 49.19 (d, 
JC-P = 6.8 Hz); 31P NMR (121 MHz, DMSO) δ = 10.63 (JC-Pt = 1953 Hz); IR (neat) ṽ = 692, 
704, 725, 755, 872, 890, 1036, 1114, 1148, 1179, 1192, 1270, 1332, 1388, 1438, 1481, 
1508, 1631, 3001, 3044 cm-1; HRMS for DMSO adduct calcd. for C21H22Cl2F3NOPPtS: 
689.013152; found: 689.014029. 
 
 
General procedure for the preparation of the phosphine gold complexes. AuCl·SMe2 (1 
equiv.) was added to a solution of the desired pyridiniophosphine salt (1 equiv.) in DCM (2 
ml) and the resulting suspension stirred for 1 hour at rt. After evaporation of the solvent, the 





Compound 30: Prepared from 12 (100 mg, 0.274 mmol) and AuCl·SMe2 
(80.7 mg, 0.274 mmol) following the general procedure. White solid (159 
mg, 99%).  
1H NMR (300 MHz, CDCl3) δ = 9.06 (d, J = 0.5 Hz, 1H), 8.44 (t, J = 7.7 Hz, 1H), 8.20 (t, J = 
6.4 Hz, 1H), 7.86 – 7.53 (m, 10H), 7.38 (t, J = 7.5 Hz, 1H), 4.45 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ = 151.71, 147.12 (d, JC-P = 52.2 Hz), 145.39 (d, J = 5.6 Hz), 134.83 (d, JC-P = 15.6 
Hz), 134.05 (d, JC-P = 2.0 Hz), 133.77 (d, JC-P = 9.3 Hz), 130.48 (d, JC-P = 12.8 Hz), 122.55, 
121.90, 48.64 (d, JC-P = 11.4 Hz); 31P NMR (121 MHz, CDCl3) δ = 30.88; IR (neat) ṽ = 692, 
729, 913, 998, 1055, 1097, 1162, 1185, 1278, 1438, 1482, 1500, 1609, 3061, 3138 cm-1; 
HRMS calcd. for C18H17NAuClP: 510.044722; found: 510.044585. 
 
 
Compound 31: Prepared from 14 (50 mg, 0.12 mmol) and AuCl·SMe2 
(34.5 mg, 0.12 mmol) following the general procedure. White solid (53 
mg, 68%).  
1H NMR (400 MHz, CD3CN) δ = 8.94 (s, 1H), 8.63 (t, J = 8.0 Hz, 1H), 
8.29 (t, J = 6.7 Hz, 1H), 7.83 – 7.59 (m, 12H), 7.43 (t, J = 8.0 Hz, 2H), 7.23 (d, J = 7.9 Hz, 
2H); 13C NMR (101MHz, CD3CN) δ = 152.22, 148.28 (d, JC-P = 5.2 Hz), 141.55 (d, JC-P = 4.5 
Hz), 136.26 (d, JC-P = 15.9 Hz), 136.10 (d, JC-P = 8.2 Hz), 134.89 (d, JC-P = 2.5 Hz), 133.32, 
131.31 (d, JC-P = 3.2 Hz), 131.17, 131.01, 127.87, 125.84, 125.22; 31P NMR (162 MHz, 
CD3CN) δ = 31.36; IR (neat) ṽ = 668, 689, 712, 735, 753, 765, 786, 853, 926, 980, 997, 
1030, 1044, 1099, 1144, 1162, 1189, 1256, 1283, 1433, 1442, 1458, 1483, 1587, 1603, 3060 
cm-1; HRMS calcd. for C23H19NAuClP: 572.060365; found: 572.060083. 
 
 
Compound 32: Prepared from 15 (100 mg, 0.26 mmol) and AuCl·SMe2 
(76.6 mg, 0.26 mmol) following the general procedure. White solid 
(166 mg, 97%).  
1H NMR (400 MHz, CD3CN) δ = 9.02 (dd, J = 6.0 Hz, 2.7, 1H), 8.27 (ddd, 
J = 9.1, 6.6, 2.6 Hz, 1H), 7.88 – 7.63 (m, 10H), 7.58 – 7.48 (m, 1H), 4.40 (s, 3H); 13C NMR 
(101MHz, CD3CN) δ = 162.24 (d, JC-F = 260.5 Hz), 142.99 (d, JC-P = 37.3 Hz), 137.51 (dd, JC-
F =10.0 Hz, JC-P = 8.4 Hz), 136.23 (d, JC-P = 15.9 Hz), 135.36 (d, JC-P = 2.6 Hz), 133.81 (d, JC-
P = 6.2 Hz), 133.58 (d, JC-P = 6.3 Hz), 131.65 (d, JC-P = 12.8 Hz), 123.98 (d, JC-P = 62.6 Hz), 
50.70 (d, JC-P = 11.9 Hz); 31P NMR (162 MHz, CD3CN) δ = 28.68; IR (neat) ṽ = 690, 717, 737, 
751, 852, 964, 996, 1034, 1048, 1170, 1279, 1437, 1478, 1505, 1594, 1615, 3055, 3079 
cm-1; HRMS calcd. for C18H16NAuClFP: 528.035295; found: 528.035127. 
  
 
Compound 33: Prepared from 16 (100 mg, 0.23 mmol) and 
AuCl·SMe2 (68 mg, 0.23 mmol) following the general procedure. White 
solid (151 mg, 99%). 
 1H NMR (300 MHz, CD3CN) δ = 9.38 (s, 1H), 8.80 – 8.71 (m, 1H), 
7.90 – 7.67 (m, 11H), 4.47 (s, 3H); 13C NMR (75 MHz, CD3CN) δ = 153.75 (d, JC-P = 46.8 Hz), 
150.38 (d, JC-P = 2.5 Hz), 143.92 (td, JC-P = 6.1, JC-F = 3.0 Hz), 136.42 (d, JC-P = 15.7 Hz), 
136.41, 135.62 (d, JC-P = 2.7 Hz), 133.42 – 131.99 (dq, JC-P =37.1 Hz, JC-F = 1.6 Hz), 131.74 
(d, JC-P = 13.0 Hz), 123.16 (d, JC-P = 64.7 Hz), 122.07 (q, JC-F = 273.3 Hz), 50.82 (d, JC-P = 
11.3 Hz); 19F NMR (282 MHz, CDCl3) δ= -63.71, -151.49, -151.54; 31P NMR (121 MHz, 
CD3CN) δ = 31.54; IR (neat) ṽ = 691, 705, 715, 752, 873, 892, 996, 1053, 1118, 1162, 1200, 
1280, 1334, 1393, 1440, 1481, 1510, 1590, 1634, 3092 cm-1; HRMS calcd. for C20H18F3NP: 
578.032104; found: 578.032257. 
 
Compound 34: Prepared from 19(SbF6) (160 mg, 0.18 mmol) and 
AuCl·SMe2 (54.3 mg, 0.18 mmol) following the general procedure to yield 
34 as a white solid (104 mg, 51%). 
1H NMR (400 MHz, CD3CN) δ = 9.42 (s, 1H), 8.77 (d, J = 8.4 Hz, 1H), 
8.47 (s, 2H), 8.29 (d, J = 13.8 Hz, 4H), 7.89 (t, J = 7.8 Hz, 1H), 4.80 (qd, 
J = 7.1, 1.0 Hz, 2H), 1.64 (t, J = 7.2 Hz, 3H); 13C NMR (101 MHz, 
CD3CN) δ = 149.19, 144.37 (dd, JC-P = 6.0 Hz, JC-F = 3.1 Hz), 138.51 (d, 
JC-P = 9.8), 137.13 (d, JC-P = 3.1), 136.96 (d, JC-P = 3.0), 134.11 (qd, JC-F = 34.5 Hz, JC-P = 
13.3 Hz), 134.00 (d, JC-P = 37.6 Hz), 130.09 (d, JC-P = 2.9 Hz), 126.33 (d, JC-P = 64.9), 123.64 
(q, JC-F = 272.5), 121.94 (q, JC-F = 268.7 Hz), 58.97 (d, JC-P = 12.4), 16.47; 19F NMR (282 
MHz, CDCN) δ = -63.49, -63.59, -124.01 (sext, JF-121Sb = 1940 Hz) , -124.01 (oct, JF-123Sb = 
1060 Hz); 31P NMR (121 MHz, CD3CN) δ = 32.21; IR (neat) ṽ = 681, 699, 718, 731, 742, 764, 
847, 866, 899, 927, 997, 1032, 1058, 1097, 1123, 1186, 1280, 1337, 1358, 1405, 1447, 




























































Compound 6: 13C NMR (75 MHz, CD3CN) 





















Compound 7 : 1H NMR (300 MHz, CDCl3) 





























































































































































Compound 8: 13C NMR (75 MHz, CD3CN) 


































Compound 8: 19F NMR (282 MHz, CD3CN) 















Compound 9: 1H-NMR (300 MHz, CD3CN) 







































































































































Compound 10: 1H NMR (300 MHz, CDCN)  











































Compound 10: 13C NMR (75 MHz, CDCN)  
  






















































































































Compound 11: 1H-NMR (300 MHz, CD3CN) 
  


































































































































































































































































Compound 12: 31P (121 MHz, CDCl3): 







Compound 13: 1H NMR (400 MHz, CDCl3) 















































































































Compound 13: 31P NMR (162 MHz, CDCl3) 





Compound 13: 13C NMR (101 MHz, CDCl3) 
  





















































































































































































































Compound 14: 31P NMR (121 MHz, CDCN)  
  










































































































































































































































































Compound 15: 31P NMR (75 MHz, CDCN)  
  








Compound 16: 1H NMR (300 MHz, CDCN) 


















































































































































































Compound 16: 31P NMR (121 MHz, 
CD3CN)








Compound 17: 1H NMR (300 MHz, CDCl3) 
















































































Compound 17: 13C NMR (282 MHz, CDCN) 



























































































































Compound 17: 31P NMR (121 MHz, CDCN)  








Compound 18: 1H NMR (300 MHz, CDCN) 






































































































































































































































































Compound 18: 31P NMR (121 MHz, CDCN)  
  




















































Compound 19: 13C NMR (75 MHz, CDCN) 
  







































































































































































































































Compound 19: 31P NMR (121 MHz, CDCN)  
  































































Compound 20: 13C NMR (75 MHz, CDCN) 
  



























































































































Compound 20: 31P NMR (121 MHz, CDCN)  









Compound 21: 1H NMR (300 MHz, CDCN) 
  










































Compound 21: 13C NMR (75 MHz, CDCN) 






















































































Compound 21: 31P NMR (121 MHz, CDCN)  
  
 













































Compound 22: 13C NMR (75 MHz, CDCN) 
  

























































































































Compound 22: 31P NMR (121 MHz, CDCN)  









Compound 23: 1H NMR (300 MHz, CDCl3) 
  




































































Compound 23: 13C NMR (75 MHz, CD3CN) 


















































































































Compound 23: 31P NMR (121 MHz,CDCl3) 
  














































































































































Compound 28: 13C NMR (75 MHz, DMSO) 
  


































































































Compound 28: 31P NMR (162 MHz, d6-DMSO/CD3CN) 



















Compound 29: 1H NMR (300 MHz, d6-DMSO) 
  



































































































































































































































Compound 30: 1H NMR (300 MHz, CDCl3) 

















































Compound 30: 13C NMR (75 MHz, CDCl3) 
 
  















































Compound 30: 31P NMR (162 MHz, CDCl3) 







Compound 31: 1H NMR (400 MHz, CD3CN) 
  


































































Compound 31: 13C NMR (102 MHz, CD3CN) 






















































































































Compound 31: 31P NMR (162 MHz, CD3CN) 
  


























































































































































































































Compound 32: 31P NMR (162 MHz, CD3CN) 



































































































Compound 33: 13C NMR (75 MHz, CD3CN) 









































































































































































Compound 33: 31P NMR (162 MHz, CD3CN) 



















































































Compound 34: 13C NMR (102 MHz, CD3CN) 























































































































































































































































































































Compound 34: 31P NMR (162 MHz, CD3CN) 
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